''I'm a human being first, and a star second.'' + An interview with Vladimir Malakhov

被引：0
|
作者：
Regitz, H
Malakhov, V
机构：
来源：
BALLETT INTERNATIONAL-TANZ AKTUELL | 1997年 / 02期
关键词：
D O I：
暂无
中图分类号：
J7 [舞蹈];
学科分类号：
摘要：
引用
收藏
页码：26 / 29
页数：4
相关论文
共 50 条
  • [41] BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study
    Hu, X.
    Zheng, X.
    Mo, H.
    Cui, X.
    Ding, L.
    Tan, F.
    Hu, P.
    Shi, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] Re: First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors Editorial Comment
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2016, 196 (01): : 61 - 61
  • [43] First-in-human phase I study: Results of a second-generation non-ansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors.
    Mahadevan, Daruka
    Rensvold, Diane M.
    Kurtin, Sandra E.
    Cleary, James M.
    Gandhi, Leena
    Lyons, John F.
    Lock, Victoria
    Lewis, Samantha
    Shapiro, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study.
    Hu, Xingsheng
    Zheng, Xin
    Mo, Hongnan
    Cui, Xinge
    Ding, Lieming
    Tan, Fenlai
    Hu, Pei
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] A first-in-human, phase I trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem cells (CSC) in patients with advanced solid tumors
    Smith, D. C.
    Eisenberg, P.
    Stagg, R.
    Manikhas, G.
    Pavlovskiy, A.
    Sikic, B.
    Kapoun, A.
    Benner, S. E.
    EJC SUPPLEMENTS, 2010, 8 (07): : 73 - 73
  • [46] Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I
    Gregson, J.
    Rhee, S. Y.
    Datir, R.
    Pillay, D.
    Perno, C. F.
    Derache, A.
    Shafer, R. S.
    Gupta, R. K.
    JOURNAL OF INFECTIOUS DISEASES, 2020, 222 (07): : 1108 - 1116
  • [47] Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of the Anti-ADAMTS-5 Nanobody®, M6495, in Healthy Male Subjects: A Phase I, Placebo-Controlled, First-in-Human Study
    Guehring, Hans
    Balchen, Torben
    Goteti, Kosalaram
    Sonne, Jesper
    Ladel, Christoph
    Ona, Victor
    Moreau, Flavie
    Bay-Jensen, Anne
    Bihlet, Asger Reinstrup
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [48] Safety and Preliminary Efficacy Results of a Phase I First-in-Human Study of the Novel Notch-1 Targeting Antibody Brontictuzumab (OMP-52M51) Administered Intravenously to Patients with Hematologic Malignancies
    Casulo, Carla
    Ruan, Jia
    Dang, Nam H.
    Gore, Lia
    Diefenbach, Catherine
    Beaven, Anne W.
    Castro, Januario E.
    Porcu, Pierluigi
    Faoro, Leonardo
    Dupont, Jakob
    Kapoun, Ann
    Wang, Min
    McGuire, Kristin
    Flinn, Ian W.
    BLOOD, 2016, 128 (22)
  • [49] Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors.
    Burris, Howard A.
    Giaccone, Giuseppe
    Im, Seock-Ah
    Bauer, Todd Michael
    Oh, Do-Youn
    Jones, Suzanne Fields
    Nordstrom, Jeffrey L.
    Li, Hua
    Carlin, David A.
    Baughman, Jan E.
    Lechleider, Robert Joseph
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] A first-in-human Phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors.
    Davis, S. Lindsey
    LoRusso, Patricia
    Xu, Lu
    Kapoun, Ann M.
    Dupont, Jakob
    Munster, Pamela
    Eckhardt, S. Gail
    Patnaik, Amita
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
12345